Cardiac involvement in patients with myeloproliferative disorders

https://doi.org/10.1016/0002-9343(92)90576-WGet rights and content

Abstract

introduction: To evaluate cardiac involvement in myeloproliferative disorders (MPD), two-dimensional and Doppler echocardiographic studies were performed in 30 patients with MPD.

patients and methods: There were 18 women and 12 men, with an age range from 35 to 76 years. Eighteen patients had polycythemia vera (PV), 8 had essential thrombocythemia (ET), and 4 had agnogenic myeloid metaplasia (AMM).

results: Echocardiography revealed valvular lesions in 19 of 30 patients (63%) compared with only 1 of 22 patients (4.5%) in a control group of patients referred for echocardiography to exclude a cardiac source for idiopathic systemic thromboembolism (χ2 = 13.39, p <0.001, by χ2 test with Yates' correction). Valvular lesions were found in 77% of patients with PV, 50% with ET, and 25% with AMM (p = NS). The aortic and mitral valves were the most commonly involved valves, and the most common echocardiographic lesion was leaflet thickening, which was found in 12 patients (40%), followed by vegetations, which were observed in 5 patients (16%). In their past history, 14 of 30 (47%) MPD patients had arterial or venous thrombosis or embolism. Twelve of 19 (63%) patients with valvular lesions had thromboembolism compared with only 2 of 11 (18%) patients without evidence of valvular lesions (χ2 = 3.99, p <0.05, by χ2 test with Yates' correction). Pulmonary hypertension, unrelated to the severity of valvular disease and probably resulting from pulmonary venous occlusion, was found in four patients (13%).

conclusions: We conclude that the heart is frequently involved in patients with MPD, particularly when their past history is complicated by a thromboembolic event. Some patients have clinically significant valvular disease. Pulmonary hypertension is another relatively common finding in MPD patients. Echocardiography provides information of clinical significance in MPD patients. A larger number of patients is needed to determine whether the presence of valvular lesions is of prognostic significance and may herald future thromboembolic events.

References (42)

  • A Wehmeier et al.

    Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease

    Haemostasis

    (1989)
  • RB Davis

    Acute thrombotic complications of myeloproliferative disorders in young adults

    Am J Clin Pathol

    (1985)
  • B Brenner et al.

    Splenectomy in agnogenic myeloid metaplasia and post-polycythemic myeloid metaplasia

    Arch Intern Med

    (1988)
  • EK Chartash et al.

    Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome

    Am J Med

    (1989)
  • NE Doherty et al.

    Echocardiographic findings in systemic lupus erythematosus

    Am J Cardiol

    (1988)
  • EK Chartash et al.

    Lupus anticoagulant associated with aortic and mitral valve insufficiency [abstract]

    Arthritis Rheum

    (1986)
  • RA Asherson et al.

    Cerebral and valve lesions in systemic lupus erythematosus associated with antiphospholipid antibodies

    J Rheumatol

    (1988)
  • PD Berg et al.

    Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols

    Semin Hematol

    (1986)
  • S Murphy

    Primary thrombocythemia

  • MN Silverstein

    Agnogenic myeloid metaplasia

    (1975)
  • AS Abbasi et al.

    Detection and estimation of the degree of mitral regurgitation by range-gated pulsed Doppler echocardiography

    Circulation

    (1980)
  • Cited by (0)

    This work was supported in part by the United States-Israel Binational Science Foundation (Grant 88-00177 to Dr. Reisner).

    View full text